Obesity, Metabolic Syndrome, and ‘Difficult-to-Treat’ Psoriatic Arthritis: Is Inflammation Only Half the Story?

Obesity, Metabolic Syndrome, and ‘Difficult-to-Treat’ Psoriatic Arthritis Is Inflammation Only Half the Story Review Abstract Psoriatic arthritis (PsA) is a chronic, immune mediated inflammatory musculoskeletal disease that affects a substantial proportion of individuals with psoriasis. Characterized by peripheral arthritis, enthesitis, dactylitis, axial involvement, and progressive joint damage, PsA is associated

Guselkumab Provides Relief For Patients Who Suffer With Psoriasis

Guselkumab Provides Relief For Patients Who Suffer With Psoriasis Overview A 52-week postmarketing surveillance study was launched to assess the safety and effectiveness of guselkumab, a human monoclonal antibody targeting the interleukin-23 subunit p19, in Japanese patients diagnosed with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis in real-world clinical

Golimumab Compliance In Long-Term Arthritis Treatment

Golimumab Compliance In Long-Term Arthritis Treatment STUDY BACKGROUND Biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are the cornerstones in treating inflammatory arthritides such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA). Tumor necrosis factor-alpha (TNFα) inhibitors, including adalimumab, infliximab and golimumab are the most commonly prescribed

Obesity, Metabolic Syndrome, and ‘Difficult-to-Treat’ Psoriatic Arthritis: Is Inflammation Only Half the Story?